Characterization of HLA-A2-restricted HPV-16 E7-specific CD8+ T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice

Gene Therapy

Volumn 13, Issue 1, 2006, Pages 67-77

  Peng, S ^a   Trimble, C ^a   He, L ^a   Tsai, Y C ^a   Lin, C T ^a,b   Boyd, D A K ^a   Pardoll, D ^a   Hung, C F ^a   Wu, T C ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Calreticulin; DNA vaccines; E7; HLA A2 transgenic mice; Human papillomavirus (HPV)

Indexed keywords

CALRETICULIN; DNA VACCINE; EPITOPE; HLA A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PLASMID DNA; PROTEIN E7;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG SYNTHESIS; FEMALE; FLOW CYTOMETRY; GENE DELETION; GENETIC CODE; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR; TUMOR CELL LINE; TUMOR GROWTH;

ANIMALS; ANTIGEN-ANTIBODY REACTIONS; CALRETICULIN; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; EPITOPES, T-LYMPHOCYTE; FEMALE; GENE THERAPY; GENETIC ENGINEERING; HLA-A2 ANTIGEN; HUMANS; IMMUNODOMINANT EPITOPES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS VACCINES; TRANSFECTION; VACCINES, DNA;

ANIMALIA; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; MUS MUSCULUS;

EID: 29244490582     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302607     Document Type: Article

References (24)

1. Hung CF, Wu TC. Improving DNA vaccine potency via modification of professional antigen presenting cells. Curr Opin Mol Ther 2003; 5: 20-24.
2. Kim JW, Hung CF, Juang J, He L, Kim TW, Armstrong DK et al. Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Therapy 2004.
3. Ressing ME, Sette A, Brandt RM, Ruppert J, Wentworth PA, Hartman M et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 1995; 154: 5934-5943.
4. Wentworth PA, Vitiello A, Sidney J, Keogh E, Chesnut RW, Grey H et al. Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice. Eur J Immunol 1996; 26: 97-101.
5. Newberg MH, Smith DH, Haertel SB, Vining DR, Lacy E, Engelhard VH. Importance of MHC class 1 alpha2 and alpha3 domains in the recognition of self and non-self MHC molecules. J Immunol 1996; 156: 2473-2480.
6. Satoi J, Murata K, Lechmann M, Manickan E, Zhang Z, Wedemeyer H et al. Genetic immunization of wild-type and hepatitis C virus transgenic mice reveals a hierarchy of cellular immune response and tolerance induction against hepatitis C virus structural proteins. J Virol 2001; 75: 12121-12127.
7. Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ, Liang TJ. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci USA 2003; 100: 6753-6758.
8. Diamond DJ, York J, Sun JY, Wright CL, Forman SJ. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 1997; 90: 1751-1767.
9. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de JB, Drijfhout JW et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993; 23: 2242-2249.
10. Vierboom MP, Feltkamp MC, Neisig A, Drijfhout JW, ter Schegget J, Neefjes JJ et al. Peptide vaccination with an anchor-replaced CTL epitope protects against human papillomavirus type 16-induced tumors expressing the wild-type epitope. J Immunother 1998; 21: 399-408.
11. Schreurs MW, Scholten KB, Kueter EW, Ruizendaal JJ, Meijer CJ, Hooijberg E. In vitro generation and life span extension of human papillomavirus type 16-specific, healthy donor-derived CTL clones. J Immunol 2003; 171: 2912-2921.
12. Lemonnier FA. The utility of H-2 class I knockout mice. Virus Res 2002; 82: 87-90.
13. Barra C, Perarnau B, Gerlinger P, Lemeur M, Gillet A, Gibier P et al. Analysis of the HLA-Cw3-specific cytotoxic T lymphocyte response of HLA-B7 X human beta 2m double transgenic mice. J Immunol 1989; 143: 3117-3124.
14. Engelhard VH, Lacy E, Ridge JP. Influenza A-specific, HLA-A2.1-restricted cytotoxic T lymphocytes from HLA-A2.1 transgenic mice recognize fragments of the M1 protein. J Immunol 1991; 146: 1226-1232.
15. Eiben GL, Velders MP, Schreiber H, Cassetti MC, Pullen JK, Smith LR et al. Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice. Cancer Res 2002; 62: 5792-5799.
16. Bauer M, Wagner H, Lipford GB. HPV type 16 protein E7 HLA-A2 binding peptides are immunogenic but not processed and presented. Immunol Lett 2000; 71: 55-59.
17. Street MD, Doan T, Herd KA, Tindle RW. Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein. Immunology 2002; 106: 526-536.
18. Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Ling M et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 2001; 108: 669-678.
19. Chen C-H, Wang T-L, Hung C-F, Yang Y, Young RA, Pardoll DM et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 2000; 60: 1035-1042.
20. Shen Z, Reznikoff G, Dranoff G, Rock KL. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 1997; 158: 2723-2730.
21. Kim TW, Hung CF, Boyd DA, He L, Lin CT, Kaiserman D et al. Enhancement of DNA vaccine potency by coadministration of a tumor antigen gene and DNA encoding serine protease inhibitor-6. Cancer Res 2004; 64: 400-405.
22. Lin K-Y, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August T, Pardoll DM et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56: 21-26.
23. Drijfhout JW, Brandt RM, D'Amaro J, Kast WM, Melief CJ. Detailed motifs for peptide binding to HLA-A*0201 derived from large random sets of peptides using a cellular binding assay. Hum Immunol 1995; 43: 1-12.
24. Kim TW, Hung CF, Juang J, He L, Hardwick JM, Wu TC. Enhancement of suicidal DNA vaccine potency by delaying suicidal DNA-induced cell death. Gene Therapy 2004; 11: 336-342.